Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

Core Viewpoint - Sanofi announced preliminary data from the phase II TIDE-Asthma study for its anti-OX40L mAb, amlitelimab, which showed mixed results in treating moderate-to-severe asthma, alongside updates on other respiratory pipeline candidates [1][2][3]. Group 1: Amlitelimab Study Results - The highest dose of amlitelimab did not meet the primary endpoint of annualized exacerbation rate at week 48, while the medium dose showed nominal significance [2]. - At week 60, the medium dose demonstrated clinically meaningful reductions in asthma exacerbations, with a greater reduction observed at the high dose level [3]. - Amlitelimab also led to significant improvements in lung function and asthma control, which were secondary endpoints of the study [3]. Group 2: Other Respiratory Pipeline Developments - Sanofi is developing itepekimab in partnership with Regeneron Pharmaceuticals, currently in two phase III studies for chronic rhinosinusitis with nasal polyps [5]. - Itepekimab is also being evaluated for chronic obstructive pulmonary disease (COPD), with data expected in the second half of 2025 [6]. - Additional studies are ongoing for itepekimab in bronchiectasis and for lunsekimig in high-risk asthma and moderate-to-severe asthma, with data from these studies anticipated in 2026 [8][9]. Group 3: Market Performance - Year to date, Sanofi's shares have increased by 4.9%, contrasting with a 4.9% decline in the industry [4].